Brain activation of SIRT1: Role in neuropathology

Molecular Neurobiology

Volumn 48, Issue 3, 2013, Pages 681-689

  Paraíso, Alanna Fernandes ^a   Mendes, Keila Lopes ^a,b   Santos, Sergio Henrique Sousa ^a,c  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Aging; Neurodegenerative diseases; SIRT1; Sirtuins

Indexed keywords

HUNTINGTIN; SIRTUIN 1; TRANSCRIPTION FACTOR FKHRL1;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; GENE INTERACTION; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SIGNAL TRANSDUCTION; WALLERIAN DEGENERATION;

ANIMALS; BRAIN; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84887999390     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8459-x     Document Type: Review

References (115)

1. WHO (2006) Engaging for health, Eleventh General Programme of Work, 2006-2015: a global health agenda. World Health Organization, Geneva
2. Donmez G (2012) The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol Sci 33(9):494-501
3. Vauzour D (2012) Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid Med Cell Longev 2012:914273
4. Han SH (2009) Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 5(3):120-125
5. Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78(2):547-581
6. Sun AY, Wang Q, Simonyi A, Sun GY (2010) Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 41(2-3):375-383
7. Jellinger KA, Stadelmann C (2001) Problems of cell death in neurodegeneration and Alzheimer's disease. J Alzheimers Dis 3(1):31-40
8. Spires TL, Hyman BT (2005) Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2(3):423-437
9. Rine J, Herskowitz I (1987) Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics 116(1):9-22
10. Kelly G (2010) A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. Altern Med Rev 15(3):245-263
11. Kelly GS (2010) A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev 15(4):313-328
12. Anekonda TS, Reddy PH (2006) Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 96(2):305-313
13. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA et al (2007) Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS NeurolDisord Drug Targets 6(6):411-423
14. Frye RA (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273(2):793-798
15. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404(1):1-13
16. Zakhary SM, Ayubcha D, Dileo JN, Jose R, Leheste JR, Horowitz JM et al (2010) Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems. Anat Rec (Hoboken) 293(6):1024-1032
17. Rahman S, Islam R (2011) Mammalian Sirt1: insights on its biological functions. Cell Commun Signal 9:11
18. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403(6771):795-800
19. Sinclair D (2005) Sirtuins for healthy neurons. Nat Genet 37(4):339-340
20. Sakamoto J, Miura T, Shimamoto K, Horio Y (2004) Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett 556(1-3):281-286
21. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16(10):4623-4635
22. Sahar S, Sassone-Corsi P (2012) Circadian rhythms and memory formation: regulation by chromatin remodeling. Front Mol Neurosci 5:37
23. Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S et al (2008) Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc NatlAcadSci U S A 105(40):15599-15604
24. Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J et al (2008) Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci 28(40):9989-9996
25. Barrett RM, Wood MA (2008) Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn Mem 15(7):460-467
26. Day JJ, Sweatt JD (2011) Cognitive neuroepigenetics: a role for epigenetic mechanisms in learning and memory. Neurobiol Learn Mem 96(1):2-12
27. Zocchi L, Sassone-Corsi P (2010) Joining the dots: from chromatin remodeling to neuronal plasticity. CurrOpinNeurobiol 20(4):432-440
28. Gan L, Mucke L (2008) Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58(1):10-14
29. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ et al (2011) Protective effects and mechanisms of sirtuins in the nervous system. ProgNeurobiol 95(3):373-395
30. Li Y, Xu W, McBurney MW, Longo VD (2008) SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 8(1):38-48
31. Chang HM, Wu UI, Lan CT (2009) Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res 47(3):211-220
32. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107(2):137-148
33. Nemoto S, Fergusson MM, Finkel T (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280(16):16456-16460
34. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L (2007) SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 28(1):91-106
35. Maiese K, Chong ZZ, Shang YC, Wang S (2011) Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J MorpholEmbryol 52(4):1173-1185
36. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107(2):149-159
37. Lemieux ME, Yang X, Jardine K, He X, Jacobsen KX, Staines WA et al (2005) The Sirt1 deacetylase modulates the insulin-like growth factor signaling pathway in mammals. Mech Ageing Dev 126(10):1097-1105
38. Huang J, Gan Q, Han L, Li J, Zhang H, Sun Y et al (2008) SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS One 3(3):e1710
39. Zhang J (2007) The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 282(47):34356-34364
40. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J et al (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429(6994):883-891
41. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9(2):213-219
42. Sun Y, Yao J, Kim TW, Tall AR (2003) Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 278(30):27688-27694
43. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE et al (2007) Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc NatlAcadSci U S A 104(25):10601-10606
44. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H (2005) Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7(3-4):395-403
45. Mattson MP, Meffert MK (2006) Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 13(5):852-860
46. Cao SX, Dhahbi JM, Mote PL, Spindler SR (2001) Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. Proc NatlAcadSci U S A 98(19):10630-10635
47. Mattson MP, Duan W, Chan SL, Cheng A, Haughey N, Gary DS et al (2002) Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. Neurobiol Aging 23(5):695-705
48. Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6(1):11-22
49. Van Ham TJ, Breitling R, Swertz MA, Nollen EA (2009) Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol Med 1:360-370
50. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356
51. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3:75-80
52. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120:545-555
53. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101:1172-1184
54. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120(4):483-495
55. Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58(4):495-505
56. Gibson GE, Blass JP, Beal MF, Bunik V (2005) The alpha-ketoglutarate- dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol 31(1-3):43-63
57. Selkoe DJ (2006) Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise. J Alzheimers Dis 9(3 Suppl):163-168
58. Gandy S, Martins RN, Buxbaum J (2003) Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 17(4):259-266
59. Selkoe DJ, Podlisny MB (2002) Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 3:67-99
60. Vincent B (2004) ADAM proteases: protective role in Alzheimer's and prion diseases? Curr Alzheimer Res 1(3):165-174
61. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M et al (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc NatlAcadSci U S A 96(7):3922-3927
62. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J (1994) beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun 200(2):710-715
63. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF et al (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc NatlAcadSci U S A 91(8):3270-3274
64. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR et al (1999) Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274(52):37111-37116
65. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21(2):195-218
66. Monsonego A, Weiner HL (2003) Immunotherapeutic approaches to Alzheimer's disease. Science 302(5646):834-838
67. Qin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R et al (2006) Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in squirrel monkeys (Saimiri sciureus). J Alzheimers Dis 10(4):417-422
68. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE et al (2008) A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc NatlAcadSci U S A 105(9):3374-3379
69. Qin Z, Sun Z, Huang J, Hu Y, Wu Z, Mei B (2008) Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). NeurosciLett 444(3):217-221
70. Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305(5686):1010-1013
71. Bedalov A, Simon JA (2004) Neuroscience. NAD to the rescue. Science 305(5686):954-955
72. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J et al (2005) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging 26(7):995-1000
73. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N et al (2005) Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 19(6):659-661
74. Duan W, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 57:195-206
75. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S et al (2005) SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 280(48):40364-40374
76. Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG et al (2006) NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci 23(7):1711-1720
77. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23(12):2369-2380
78. Mattson MP (2003) Will caloric restriction and folate protect against AD and PD? Neurology 60(4):690-695
79. Nathan C, Calingasan N, Nezezon J, Ding A, Lucia MS, La Perle K et al (2005) Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med 202(9):1163-1169
80. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142(2):320-332
81. Kim EJ, Kho JH, Kang MR, Um SJ (2007) Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 28(2):277-290
82. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953-966
83. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L et al (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281(31):21745-21754
84. You H, Mak TW (2005) Crosstalk between p53 and FOXO transcription factors. Cell Cycle 4(1):37-38
85. Gilley J, Coffer PJ, Ham J (2003) FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162(4):613-622
86. Devine MJ, Gwinn K, Singleton A, Hardy J (2011) Parkinson's disease and alpha-synuclein expression. Mov Disord 26(12):2160-2168
87. Zhang A, Wang H, Qin X, Pang S, Yan B (2012) Genetic analysis of SIRT1 gene promoter in sporadic Parkinson's disease. Biochem Biophys Res Commun 422(4):693-696
88. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L (2012) SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci 32(1):124-132
89. Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G et al (2009) The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem 110(5):1445-1456
90. Raghavan A, Shah ZA (2012) Sirtuins in neurodegenerative diseases: a biological-chemical perspective. Neurodegener Dis 9(1):1-10
91. Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A (2009) PGC-1{alpha} andPGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem 284:21379-21385
92. Chao J, Yu MS, Ho YS, Wang M, Chang RC (2008) Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med 45:1019-1026
93. Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T, Akaike A (2007) Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol 73:550-560
94. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787-795
95. Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ (1985) The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 312(22):1418-1421
96. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979-980
97. Borland MK, Trimmer PA, Rubinstein JD, Keeney PM, Mohanakumar K, Liu L et al (2008) Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener 3:21
98. Gomez C, Bandez MJ, Navarro A (2007) Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front Biosci 12:1079-1093
99. Pallas M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A (2008) Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov 3(1):61-69
100. Gatchel JR, Zoghbi HY (2005) Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 6(10):743-755
101. Huber K, Superti-Furga G (2011) After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem 19(12):3616-3624
102. Anonymous (1993) The Huntington's Disease Collaborative Research Group. Cell 72:971-983
103. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H et al (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37(4):349-350
104. Borrell-Pages M, Zala D, Humbert S, Saudou F (2006) Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 63(22):2642-2660
105. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1):59-69
106. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434(7029):113-118
107. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR et al (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18(1):159-165
108. Tang BL, Chua CE (2008) SIRT1 and neuronal diseases. Mol Aspects Med 29(3):187-200
109. Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, Wagner D et al (2000) A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc NatlAcadSci U S A 97(21):11377-11382
110. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D et al (2001) Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 4(12):1199-1206
111. Zhang T, Kraus WL (2010) SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta 1804(8):1666-1675
112. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA (2011) Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab 31(4):1003-1019
113. Raval AP, Dave KR, Perez-Pinzon MA (2006) Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 26(9):1141-1147
114. Rosen DR (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364:362
115. Kiaei M (2008) Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008:418765